Trial · NCT00932451
Results by group892
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 892
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Duration of Response (DR) | Crizotinib 250 mg BID | ALK Positive by IUO, N=491 | 11.8 | 95% Confidence Interval 10.4 to 12.8 | Months |
| Duration of Response (DR) | Crizotinib 250 mg BID | ALK Positive by non-IUO only, N=64 | 9.5 | 95% Confidence Interval 6.9 to 15.2 | Months |
| Time to Tumor Response (TTR) | Crizotinib 250 mg BID | ALK Positive by IUO (n=491) | 6.1 | Full Range 2.7 to 164 | Weeks |
| Time to Tumor Response (TTR) | Crizotinib 250 mg BID | ALK Positive by non-IUO only (n=64) | 6.3 | Full Range 4.7 to 65.9 | Weeks |
| Disease Control Rate (DCR) | Crizotinib 250 mg BID | ALK Positive by IUO at Week 6, N=908 | 81.7 | 95% Confidence Interval 79.0 to 84.2 | Percentage of participants |
| Disease Control Rate (DCR) | Crizotinib 250 mg BID | ALK Positive by IUO at Week 12, N=908 | 70.8 | 95% Confidence Interval 67.7 to 73.8 | Percentage of participants |
| Disease Control Rate (DCR) | Crizotinib 250 mg BID | ALK Positive by non-IUO at Week 6, N=158 | 69.6 | 95% Confidence Interval 61.8 to 76.7 | Percentage of participants |
| Disease Control Rate (DCR) | Crizotinib 250 mg BID | ALK Positive by non-IUO at Week 12, N=158 | 61.4 | 95% Confidence Interval 53.3 to 69.0 | Percentage of participants |
| Progression Free Survival (PFS) | Crizotinib 250 mg BID | ALK Positive by IUO , N= 908 | 8.4 | 95% Confidence Interval 7.1 to 9.7 | Months |
| Progression Free Survival (PFS) | Crizotinib 250 mg BID | ALK Positive by non-IUO only , N=158 | 6.9 | 95% Confidence Interval 5.6 to 9.4 | Months |
| Overall Survival (OS) | Crizotinib 250 mg BID | ALK-positive by IUO (N= 908) | 21.8 | 95% Confidence Interval 19.4 to 24.0 | Months |
| Overall Survival (OS) | Crizotinib 250 mg BID | ALK-positive by non-IUO (N= 158) | 16.9 | 95% Confidence Interval 13.4 to 21.5 | Months |
| Probability of Survival | Crizotinib 250 mg BID | ALK positive by IUO at 6 Months | 81.7 | 95% Confidence Interval 79.0 to 84.0 | Percentage of probability |
| Probability of Survival | Crizotinib 250 mg BID | ALK positive by non IUO at 6 Months | 77.5 | 95% Confidence Interval 70.1 to 83.3 | Percentage of probability |
| Probability of Survival | Crizotinib 250 mg BID | ALK positive by IUO at 12 Months | 66.5 | 95% Confidence Interval 63.3 to 69.5 | Percentage of probability |
| Probability of Survival | Crizotinib 250 mg BID | ALK positive by non IUO at 12 Months | 62.4 | 95% Confidence Interval 54.3 to 69.6 | Percentage of probability |
| Plasma Concentrations of Crizotinib (PF-02341066) and Its Metabolite PF-06260182 | Crizotinib (PF-02341066) | Cycle 1 Day 1 (N= 13, 13) | 1.95 | Geometric Coefficient of Variation 55 | ng/mL |
| Plasma Concentrations of Crizotinib (PF-02341066) and Its Metabolite PF-06260182 | PF-06260182 | Cycle 1 Day 1 (N= 13, 13) | 0.00601 | Geometric Coefficient of Variation 167 | ng/mL |
| Plasma Concentrations of Crizotinib (PF-02341066) and Its Metabolite PF-06260182 | Crizotinib (PF-02341066) | Cycle 2 Day 1 (N=447, 431) | 279 | Geometric Coefficient of Variation 46 | ng/mL |
| Plasma Concentrations of Crizotinib (PF-02341066) and Its Metabolite PF-06260182 | PF-06260182 | Cycle 2 Day 1 (N=447, 431) | 76.2 | Geometric Coefficient of Variation 79 | ng/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00932451/results